Protagonist Therapeutics Inc (DE:PGF)
NASDAQ:PGF
PGF Stock Chart & Stats
€75.00
-€1.00(-2.69%)
At close: 4:00 PM EST
€75.00
-€1.00(-2.69%)
Day’s Range― - ―
52-Week Range€42.20 - €81.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.74B
Enterprise Value€6.98B
Total Cash (Recent Filing)€547.79M
Total Debt (Recent Filing)€9.78M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Jul 30, 2026EPS Estimate
1.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding64,311,370
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.03
Price to Sales (P/S)120.66
P/FCF Ratio99.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€102.67Price Target Upside36.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)3.46
Revenue Forecast (FY)€432.63M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetA very low debt-to-equity ratio and large equity base provide durable financial flexibility to fund R&D and absorb operating volatility. This conservative capital structure reduces near-term refinancing risk and supports multi-quarter development programs and partnering negotiations.
Exceptionally High Gross MarginsSustained ~99% gross margins reflect structural product economics for peptide therapeutics and imply that, once commercialized, revenue converts to operating income more efficiently than many peers. High margins support long-term profitability potential once scale or approvals are achieved.
Meaningful Revenue AccelerationA substantial TTM revenue increase signals improving commercialization or partnering activity, providing a durable backdrop for future milestone receipts or license income. Continued top-line momentum can underpin sustained R&D funding and validate program traction with partners.
Bears Say
Material Negative Cash FlowLarge, persistent negative operating and free cash flow increases dependence on the balance sheet or new financings. If cash burn persists over multiple quarters it can force dilutive capital raises or tighter R&D prioritization, constraining long-term program execution and optionality.
Deep, Volatile Operating LossesSevere negative margins and volatility reduce earnings quality and hurt returns on capital. The swing from prior-year profitability to large losses makes forecasting difficult, undermines operational resilience, and raises execution risk across clinical programs over the medium term.
Revenue Dependent On PartnershipsRelying on milestone, upfront, and royalty payments creates structural revenue uncertainty until products are approved. Partnership-dependence limits direct commercialization control and makes cash flow contingent on third-party decisions and clinical/regulatory outcomes.
Protagonist Therapeutics News
PGF FAQ
What was Protagonist Therapeutics Inc’s price range in the past 12 months?
Protagonist Therapeutics Inc lowest stock price was €42.20 and its highest was €81.00 in the past 12 months.
What is Protagonist Therapeutics Inc’s market cap?
Protagonist Therapeutics Inc’s market cap is €6.74B.
When is Protagonist Therapeutics Inc’s upcoming earnings report date?
Protagonist Therapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 35 days.
How were Protagonist Therapeutics Inc’s earnings last quarter?
Protagonist Therapeutics Inc released its earnings results on May 05, 2026. The company reported €0.044 earnings per share for the quarter, beating the consensus estimate of -€0.44 by €0.484.
Is Protagonist Therapeutics Inc overvalued?
According to Wall Street analysts Protagonist Therapeutics Inc’s price is currently Undervalued.
Does Protagonist Therapeutics Inc pay dividends?
Protagonist Therapeutics Inc does not currently pay dividends.
What is Protagonist Therapeutics Inc’s EPS estimate?
Protagonist Therapeutics Inc’s EPS estimate is 1.87.
How many shares outstanding does Protagonist Therapeutics Inc have?
Protagonist Therapeutics Inc has 64,311,370 shares outstanding.
What happened to Protagonist Therapeutics Inc’s price movement after its last earnings report?
Protagonist Therapeutics Inc reported an EPS of €0.044 in its last earnings report, beating expectations of -€0.44. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Protagonist Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:PGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€102.67 (36.89% Upside)
€102.67 (36.89% Upside)
Blogger Sentiment
Bullish
DE:PGF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €24.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.93%
12-Months-Change
Fundamentals
Return on Equity
-17.76%
Trailing 12-Months
Asset Growth
-6.02%
Trailing 12-Months
Company Description
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
PGF Stock 12 Month Forecast
Average Price Target
€102.67
▲(36.89% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Options Prices
Currently, No data available
---